Daniel Grosslight
Stock Analyst at Citigroup
(1.25)
# 3,667
Out of 5,147 analysts
119
Total ratings
35.53%
Success rate
-12.63%
Average return
Main Sectors:
Stocks Rated by Daniel Grosslight
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVH Evolent Health | Maintains: Buy | $6 → $4 | $3.25 | +23.08% | 7 | Feb 26, 2026 | |
| CTEV Claritev | Maintains: Buy | $63 → $21 | $13.47 | +55.90% | 5 | Feb 25, 2026 | |
| HIMS Hims & Hers Health | Maintains: Sell | $17 → $13 | $14.52 | -8.75% | 13 | Feb 24, 2026 | |
| WAY Waystar Holding | Maintains: Buy | $46 → $35 | $25.65 | +36.45% | 4 | Feb 18, 2026 | |
| TDOC Teladoc Health | Maintains: Neutral | $10 → $9 | $5.26 | +71.10% | 13 | Jan 9, 2026 | |
| PHR Phreesia | Maintains: Buy | $29 → $25 | $12.33 | +102.76% | 8 | Jan 9, 2026 | |
| HCAT Health Catalyst | Maintains: Neutral | $3.25 → $2.75 | $1.62 | +69.75% | 12 | Jan 9, 2026 | |
| GDRX GoodRx Holdings | Maintains: Buy | $5 → $4.5 | $1.87 | +140.64% | 8 | Jan 9, 2026 | |
| ACH Accendra Health | Maintains: Buy | $7 → $4 | $2.42 | +65.29% | 1 | Jan 9, 2026 | |
| CAH Cardinal Health | Upgrades: Buy | $190 → $244 | $229.23 | +6.44% | 11 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $820 → $860 | $987.37 | -12.90% | 8 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $3 → $1 | $0.59 | +69.69% | 6 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $23.75 | +5.26% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $10 | $1.30 | +669.23% | 7 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $7 → $8 | $9.94 | -19.52% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.5 → $1.25 | $0.86 | +45.33% | 5 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $7 → $3.5 | $4.82 | -27.39% | 2 | Nov 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $9.15 | +42.08% | 1 | Dec 11, 2019 |
Evolent Health
Feb 26, 2026
Maintains: Buy
Price Target: $6 → $4
Current: $3.25
Upside: +23.08%
Claritev
Feb 25, 2026
Maintains: Buy
Price Target: $63 → $21
Current: $13.47
Upside: +55.90%
Hims & Hers Health
Feb 24, 2026
Maintains: Sell
Price Target: $17 → $13
Current: $14.52
Upside: -8.75%
Waystar Holding
Feb 18, 2026
Maintains: Buy
Price Target: $46 → $35
Current: $25.65
Upside: +36.45%
Teladoc Health
Jan 9, 2026
Maintains: Neutral
Price Target: $10 → $9
Current: $5.26
Upside: +71.10%
Phreesia
Jan 9, 2026
Maintains: Buy
Price Target: $29 → $25
Current: $12.33
Upside: +102.76%
Health Catalyst
Jan 9, 2026
Maintains: Neutral
Price Target: $3.25 → $2.75
Current: $1.62
Upside: +69.75%
GoodRx Holdings
Jan 9, 2026
Maintains: Buy
Price Target: $5 → $4.5
Current: $1.87
Upside: +140.64%
Accendra Health
Jan 9, 2026
Maintains: Buy
Price Target: $7 → $4
Current: $2.42
Upside: +65.29%
Cardinal Health
Jan 9, 2026
Upgrades: Buy
Price Target: $190 → $244
Current: $229.23
Upside: +6.44%
Sep 24, 2025
Maintains: Buy
Price Target: $820 → $860
Current: $987.37
Upside: -12.90%
Aug 6, 2025
Downgrades: Neutral
Price Target: $3 → $1
Current: $0.59
Upside: +69.69%
Apr 22, 2024
Initiates: Buy
Price Target: $25
Current: $23.75
Upside: +5.26%
Aug 9, 2023
Maintains: Neutral
Price Target: $9 → $10
Current: $1.30
Upside: +669.23%
Aug 4, 2023
Downgrades: Sell
Price Target: $7 → $8
Current: $9.94
Upside: -19.52%
Apr 28, 2023
Maintains: Neutral
Price Target: $1.5 → $1.25
Current: $0.86
Upside: +45.33%
Nov 16, 2021
Downgrades: Neutral
Price Target: $7 → $3.5
Current: $4.82
Upside: -27.39%
Dec 11, 2019
Initiates: Outperform
Price Target: $13
Current: $9.15
Upside: +42.08%